StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the stock.
Oragenics Stock Performance
Shares of OGEN stock opened at $1.03 on Friday. The stock has a 50-day moving average price of $1.60. The firm has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.12 and a beta of 0.50. Oragenics has a 12 month low of $0.97 and a 12 month high of $7.74.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.70) EPS for the quarter.
Hedge Funds Weigh In On Oragenics
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Recommended Stories
- Five stocks we like better than Oragenics
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Options Trading – Understanding Strike Price
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.